DURECT Corporation (DRRX) News
Filter DRRX News Items
DRRX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
DRRX News Highlights
- DRRX's 30 day story count now stands at 3.
- Over the past 3 days, the trend for DRRX's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
Latest DRRX News From Around the Web
Below are the latest news stories about DURECT CORP that investors may wish to consider to help them evaluate DRRX as an investment opportunity.
Wall Street Analysts Think Durect (DRRX) Could Surge 594.98%: Read This Before Placing a BetThe mean of analysts' price targets for Durect (DRRX) points to a 595% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
Durect (DRRX) Reports Q1 Loss, Misses Revenue EstimatesDurect (DRRX) delivered earnings and revenue surprises of -4% and 41.81%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? |
DURECT Corporation Reports First Quarter 2023 Financial Results and Business UpdateDURECT Corporation (Nasdaq: DRRX) today announced financial results for the three months ended March 31, 2023 and provided a corporate update. |
DURECT Corporation to Announce First Quarter 2023 Financial Results and Provide Business Update on May 8- DURECT Corporation (Nasdaq: DRRX) today announced that it will report its first quarter 2023 financial results and host a conference call after the market close on Monday, May 8, 2023. |
DURECT Corporation to Host KOL Event on Alcohol-Associated HepatitisDURECT Corporation (Nasdaq: DRRX) today announced it will host a Key Opinion Leader ("KOL") event on Alcohol-Associated Hepatitis on May 16th in New York City. Topics of discussion will include the etiology and prevalence of alcohol-associated hepatitis (AH), current treatment insufficiencies and unmet need for patients with AH, biology of larsucosterol, trial design and status update for the Phase 2b AHFIRM trial in AH, and a company update on regulatory and commercial efforts ongoing for larsu |
DURECT Corporation to Participate in Fireside Chat at the H.C. Wainwright BioConnect Investor ConferenceDURECT Corporation (Nasdaq: DRRX) today announced that Dr. James Brown, President and CEO, will participate in a fireside chat hosted by Ed Arce, Managing Director, Senior Biotechnology Research Analyst, H.C Wainwright & Co., LLC at the H.C. Wainwright BioConnect Investor Conference on May 2, 2023. |
DURECT Announces Peer-Reviewed Article Accepted for Publication with Additional Data from Previously Completed Phase 2a Study of Larsucosterol in Alcohol-Associated HepatitisDURECT Corporation (Nasdaq: DRRX), a biopharmaceutical company focused on developing epigenetic modulator programs for the treatment of acute organ injury and chronic liver diseases, today announced that additional data from the company's previously completed Phase 2a trial evaluating larsucosterol in alcohol-associated hepatitis (AH) has been accepted by the peer-reviewed journal American Journal of Gastroenterology. In addition to previously reported safety and efficacy data from the 19-patien |
7 Biotech Stocks Sitting in the Sweet SpotBiotech stocks have the potential for massive profits if their companies are successful in developing drugs that are safe and marketable. |
DURECT Corporation Announces Appointment of Gail Maderis as Chair of the BoardDURECT Corporation (Nasdaq: DRRX) announced today that Gail Maderis has assumed the role of Chair of the Board of DURECT effective March 17, 2023. Ms. Maderis succeeds David Hoffmann as Chair of the Board. Mr. Hoffman has decided not to stand for re-election and will retire from the board on June 21, 2023 when his current term as a board member expires. |
DURECT Corporation (NASDAQ:DRRX) Q4 2022 Earnings Call TranscriptDURECT Corporation (NASDAQ:DRRX) Q4 2022 Earnings Call Transcript March 7, 2023 Operator: Greetings, and welcome to the DURECT Corporation Fourth Quarter 2022 Earnings Call. . I will now turn the conference over to our host, Tim Papp, Chief Financial Officer. Thank you. You may begin. Timothy Papp: Good afternoon, and welcome to DURECT Corporation’s Fourth […] |